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Introduction
Conclusion: We developed and validated a simple, sensitive and selective UHPLC-DAD method for the 
simultaneous determination in human serum of seven azole antifungals. The method was successfully applied to 
patient samples and is suitable for clinical applications, such as therapeutic drug monitoring.
A method was developed and validated for the simultaneous determination of 
7 azole antifungal drugs in serum utilizing ultra high-pressure liquid 
chromatography and diode array detection (UHPLC-DAD). 
These antifungals are as well imidazole drugs (miconazole and
ketoconazole) as triazole drugs (fluconazole, posaconazole, 
voriconazole, itraconazole and its active metabolite, hydroxy-
itraconazole) (Fig. 1). They are marketed in Belgium and can be administered 
orally or parenterally. 
Their determination in serum can help the clinician to adjust the dose 
administered to patients,
in order to avoid insufficient concentrations or overdose. 
• Quantification wavelengths
Voriconazole 255 nm                         
Posaco-, (hydroxy-)itraconazole 260 nm 
Fluco-, keto-, mico-, azaconazole 210 nm
• Mobile phase: gradient mode (Fig. 4)
(A) acetonitrile; (B) NH4HCO3 10 M pH10 
• Flow rate: 0,4 ml/min
• Injection volume: 5 µl
Material and method
• Sample pre-treatment: an internal standard (azaconazole – Fig. 2) is added to 1 ml of serum sample before liquid-liquid extraction.
• Equipment: Acquity® UPLC system (Waters Corporation®) coupled to a DAD (Fig. 3)
• Column: Acquity® BEH C18 (Waters Corporation®) 150 mm x 2.1 mm, 1.7 µm / T°: 40°C
Results
• Validation method: according to the total error method approach by using an analytical validation software (e•noval V3.0 Arlenda®).                   
→ Calibration standards: in duplicate during 3 days (7 levels) - Validation standards: in triplicate during 3 days (8 levels)
The seven azole antifungals were identified together over a 13-min run time (Fig. 5).
All calibration curves showed good linearity (r² > 0.99) in ranges considered clinically satisfactory (Fig. 6, Table 1).
The assay was specific and linear from 0.05 to 10 mg/L for voriconazole (VZ), posaconazole (PZ), itraconazole (IZ), hydroxy-itraconazole
(HIZ) and ketoconazole (KZ); from 0.3 to 10 mg/L for fluconazole (FZ) and from 0.1 to 10 mg/L for miconazole (MZ) (Table 1).
Fig. 2: Chemical structure 
of azaconazole (= IS).
Fig. 6: Calibration curves of each azole antifungal drug.Fig. 5: Chromatogram of seven azole antifungal drugs and internal standard.
Fig. 1: Chemical structures of imidazole and triazole antifungal drugs. 
Fig. 4: Gradient of mobile 
phase.
Fig. 3: UHPLC-DAD 
system.
Table 1: Limits of quantification (LOQ), limits of 
linearity (LOL) and therapeutic intervals of each
azole antifungal drug.
Active metabolite
The trueness and precision values for intra-
and inter-assays were lower than 10% and 
than 15%, respectively, for all drugs.
